Neurocrine Biosciences (NBIX) Stock Forecast & Price Target

Neurocrine Biosciences is well positioned by a diversified commercial base, with INGREZZA still showing record new-patient additions and TRx, 2Q26 revenue of $959 million, and a raised FY26 guide to $2.825 billion to $2.875 billion, while CRENESSITY and VYKAT XR add additional durable growth pillars. The bull case is strengthened by expectations that INGREZZA can approach about $3.0 billion to $3.5 billion by 2028, CRENESSITY can exceed $1 billion by 2030, and VYKAT XR can become a meaningful high-margin rare-disease franchise as launch normalization improves. Beyond the marketed portfolio, a deep pipeline with multiple 2027 to 2028 readouts in MDD, schizophrenia, and obesity creates substantial upside optionality and supports a favorable long-term growth outlook.

Neurocrine Biosciences is facing a weakening fundamental setup because Ingrezza’s tardive dyskinesia growth may slow as the market matures, while Huntington’s chorea is already small and served by two approved products, limiting meaningful share gains. Crenessity also faces competitive pressure from atumelnant, and the broader pipeline carries execution risk after osavampator’s Phase 2 results showed a non-monotonic dose response, making Phase 3 readouts less certain. Even with Ingrezza still profitable, management expects a revenue dip from 2028 to 2029 as IRA pricing hits from 2029, and FY29E revenue falls to $2,990MM from $3,375MM, reinforcing a cautious outlook.